研究セミナー Driving out a tumor driver: dislodging Hexokinase 2 from mitochondria/ER contact sites to kill neoplastic cells
講演 | |
---|---|
日時 | 2025年4月28日(月)17:00~18:00 |
場所 | 生命システム棟2階セミナー室 |
言語 | 英語 |
世話人 |
岡本浩二 |
Hexokinase 2 (HK2) is a metabolic enzyme overexpressed by the majority of neoplastic cells. HK2 resides in mitochondria/ER contact sites (MAM) of tumor cells where it exerts a potent antiapoptotic function. Indeed, HK2 expression is associated to treatment resistance and worst prognosis in patients. In parallel, its genetic ablation in mice bearing tumors is curative. As a consequence, HK2 is a promising target for an antineoplastic therapy. For this reason, we designed and tested an innovative and translatable trojan horse approach that dislodges HK2 from MAMs, rapidly induces mitochondrial Ca2+ overload and triggers tumor cell death in different models.
